Agendia Revenue and Competitors
Estimated Revenue & Valuation
- Agendia's estimated annual revenue is currently $46.1M per year.
- Agendia received $35.0M in venture funding in July 2018.
- Agendia's estimated revenue per employee is $193,750
- Agendia's total funding is $182.3M.
Employee Data
- Agendia has 238 Employees.
- Agendia grew their employee count by -16% last year.
Agendia's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Sr. VP Global Operations | Reveal Email/Phone |
3 | Global VP Reimbursement & Government Affairs | Reveal Email/Phone |
4 | Sr VP Research and Development & Innovation | Reveal Email/Phone |
5 | SVP General Manager | Reveal Email/Phone |
6 | VP Market Development and Innovation | Reveal Email/Phone |
7 | VP, Program Management Office | Reveal Email/Phone |
8 | SVP Compliance | Reveal Email/Phone |
9 | VP Product and Software Development | Reveal Email/Phone |
10 | VP Global Finance | Reveal Email/Phone |
Agendia Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Agendia?
We believe in delivering precision oncology to patients and physicians, empowering them with clear answersand peace of mindabout their treatment management path. Agendia is a leading precision oncology company that brings cutting-edge genomics research into routine clinical practice. Our MammaPrint and BluePrint tests help physicians with complex treatment management decisions for women with early-stage breast cancer, delivering added insight from the individual genomic signature of their patient's tumor. We are committed to pursuing the best science, which has been validated through our collaborations with leading cancer centers, academic groups and pharmaceutical companies, in the form of landmark trials such as MINDACT, and the ongoing ISPY-2 trial, and our FLEX and PRECiSE Big Data studies.
keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals
$182.3M
Total Funding
238
Number of Employees
$46.1M
Revenue (est)
-16%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Agendia News
Abbott Laboratories, Agendia, Agilent Technologies, Ambry Genetics, Biocept, Biotheranostics, Centogene, Danaher Corporation, EXACT Sciences...
IRVINE, Calif. & AMSTERDAM, Netherlands--(BUSINESS WIRE)--Agendia, Inc., a commercial stage company focused on enabling optimized...
IRVINE, Calif., Nov. 5, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the 2020 Canaccord Genuity Virtual MedTech & Diagnostics Forum, which takes place November 19, 2020. Agendia Chief Executive Mark Straley wil ...
Laura van 't Veer among 15 trailblazers in oncology honored at the 2020 virtual awards ceremony IRVINE, Calif., Oct. 28, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that co-founder and Chief Research Officer Laura van 't Veer, Ph ...
IRVINE, Calif., Oct. 15, 2020 /PRNewswire/ -- Agendia, Inc., a world leader in precision oncology for breast cancer, today announced its participation in the 2020 Stifel Virtual Healthcare Conference, which takes place November 16-18, 2020. Agendia Chief Executive Mark Straley will present on ...
Other Companies in Irvine
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $38.1M | 239 | 56% | N/A |
#2 | $7.5M | 239 | 7% | N/A |
#3 | $66.5M | 241 | 7% | N/A |
#4 | $43.4M | 242 | 12% | N/A |
#5 | $82.2M | 245 | 25% | N/A |
Agendia Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2009-09-23 | $23.0M | E | Article | |
| 2012-06-01 | $65.0M | Undisclosed | Debiopharm Group | Article |
| 2018-07-26 | $35.0M | Undisclosed | Athyrium Capital Management LP | Article |